IgA肾病牛津分类的可重复性及评分差异对治疗分配和临床相关性的影响:VALIGA研究队列证据
VALIGA研究纳入13个欧洲国家1147例IgA肾病患者,比较本地与中心病理医师对MEST-C评分的可重复性及其对糖皮质激素/免疫抑制治疗决策和长期结局的影响。结果显示所有肾小球病变(M、E、C、S)的本地评分均独立关联治疗决策,但可重复性仅S和T为中等,M、E、C较差;评分差异显著影响牛津分类的预后价值。
要点
- 本地与中心病理医师对MEST-C评分的可重复性有限,M、E、C一致性差,S和T中等。
- 所有肾小球病变(M、E、C、S)的本地评分独立关联免疫抑制治疗决策,而肾小管间质病变严重程度不关联。
- 评分差异影响牛津分类的预后价值,提示需更详细的病理评分指南。
核心结论
- 本地病理医师与中心审阅者在MEST-C评分上的差异显著影响牛津分类的预后价值。
- 由于免疫抑制治疗决策与MEST-C评分密切相关,本研究提示需要更详细的IgA肾病活检评分指南。
研究设计与样本
- VALIGA研究为多中心队列,纳入13个欧洲国家1147例IgA肾病患者。
- 活检由本地病理医师评分后,在牛津进行中心审阅。
主要发现
- 所有肾小球病变(M、E、C、S)的本地评分均独立关联是否给予糖皮质激素/免疫抑制治疗,而肾小管间质病变严重程度不关联。
- 本地与中心评分可重复性:S和T为中等,M、E、C较差。
- 除S病变中心审阅更频繁外,本地病理医师发现每种病变的统计频率均更高。
- 当受累肾小球比例较低时,分歧更易发生。
- 中心审阅评估的M病变与就诊时疾病严重程度相关性更好,区分结局更佳;而本地评估的E病变与临床表现和结局相关性更好;C和S不一致时临床表型介于双缺失(较轻)和双存在(较重)之间。
临床怎么用
- 临床解读IgA肾病牛津分类时需注意本地与中心病理评分差异对预后判断的影响。
- 免疫抑制治疗决策应谨慎结合MEST-C评分,并考虑评分可重复性局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The VALidation of IGA (VALIGA) study investigated the utility of the Oxford Classification of immunoglobulin A nephropathy (IgAN) in 1147 patients from 13 European countries. Methods. Biopsies were scored by local pathologists followed by central review in Oxford. We had two distinct objectives: to assess how closely pathology findings were associated with the decision to give corticosteroid/immunosuppressive (CS/IS) treatments, and to determine the impact of differences in MEST-C scoring between central and local pathologists on the clinical value of the Oxford Classification. We tested for each lesion the associations between the type of agreement (local and central pathologists scoring absent, local present and central absent, local absent and central present, both scoring present) with the initial clinical assessment, as well as long-term outcomes in those patients who did not receive CS/IS. RESULTS: All glomerular lesions (M, E, C and S) assessed by local pathologists were independently associated with the decision to administer CS/IS therapy, while the severity of tubulointerstitial lesions was not. Reproducibility between local and central pathologists was moderate for S (segmental sclerosis) and T (tubular atrophy/interstitial fibrosis), and poor for M (mesangial hypercellularity), E (endocapillary hypercellularity) and C (crescents). Local pathologists found statistically more of each lesion, except for the S lesion, which was more frequent with central review. Disagreements were more likely to occur when the proportion of glomeruli affected was low. The M lesion, assessed by central pathologists, correlated better with the severity of the disease at presentation and discriminated better with outcomes. In contrast, the E lesion, evaluated by local pathologists, correlated better with the clinical presentation and outcomes when compared with central review. Both C and S lesions, when discordant between local and central pathologists, had a clinical phenotype intermediate to double absent lesions (milder disease) and double present (more severe). CONCLUSION: We conclude that differences in the scoring of MEST-C criteria between local pathologists and a central reviewer have a significant impact on the prognostic value of the Oxford Classification. Since the decision to offer immunosuppressive therapy in this cohort was intimately associated with the MEST-C score, this study indicates a need for a more detailed guidance for pathologists in the scoring of IgAN biopsies.
引用
- Bellur SS, Roberts ISD, Troyanov S, et al. Reproducibility of the Oxford classification of immunoglobulin A nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: evidence from the VALidation of IGA study cohort. Nephrol Dial Transplant. 2019. PMID: 30561721. doi:10.1093/ndt/gfy337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。